Jonathan Levitt

[Frier Levitt @FrierLevitt]

Are new PBM reimbursement models creating more challenges for independent pharmacies?

Frier Levitt's A.J. Barbarito spoke with Drug Topics at NCPA 2026 about ongoing PBM underpayment, below-cost reimbursement, and the emerging risks of cost-plus contracting.

As regulatory reforms take shape, A.J. discusses what pharmacies should be watching to protect their financial viability heading into 2027.

Watch the interview: https://t.co/iYrBWGWWgh

#PBMReform #IndependentPharmacy #PharmacyReimbursement #CostPlus #NCPA2026

[Frier Levitt @FrierLevitt]

This National Pharmacy Week, we celebrate the pharmacists and pharmacy professionals who keep patients healthy and communities strong. From counseling at the counter to navigating an ever-changing healthcare landscape, your work makes a real difference every day.

At Frier Levitt, we are proud to stand alongside the pharmacy industry as trusted legal partners. Many of our attorneys are former pharmacists, bringing both legal skill and firsthand experience to every matter.

Thank you to all pharmacists for your commitment to patient care, this week and every week.

💊 Learn more about our Pharmacy Law practice: https://t.co/tbid5Q0Iq0

#PharmacyLaw #NationalPharmacyWeek #PharmacistsInLaw #FrierLevitt

[Frier Levitt @FrierLevitt]

New federal PBM transparency requirements are changing the rules for self-funded employer health plans. Is your PBM contract ready?

CAA 2026 expands rebate pass-through, compensation disclosure, and audit requirements. But without strong contractual protections, plan sponsors could see anticipated savings offset by new or increased PBM fees.

Read what ERISA plan sponsors should review now and how to prepare for upcoming contract renewals.: https://t.co/RT80EUAfGe

#ERISA #PBM #EmployeeBenefits #HealthcareLaw #FrierLevitt

[Frier Levitt @FrierLevitt]

AI offers new opportunities for medical aesthetics practices, but also raises legal risks involving advertising, patient privacy, and liability.

Learn what practices should consider before adopting AI.

🔗 Read more: https://t.co/CrS4gIyuad

#MedicalAesthetics #ArtificialIntelligence #HealthcareLaw #FrierLevitt

[Frier Levitt @FrierLevitt]

Could FDA enforcement discretion change the peptide compounding landscape?

A potential new policy could create opportunities for pharmacies and peptide suppliers, but significant regulatory questions remain.

Read more: https://t.co/RVqlJQJp2N

#FDA #PeptideCompounding #FrierLevitt

[Frier Levitt @FrierLevitt]

Five appeals. Five fully favorable ALJ decisions.

Frier Levitt secured reversals of alleged Medicare overpayments involving advanced wound-care products and related services.

Read the case results and takeaways for providers: https://t.co/clQ9glTxVx

#Medicare #WoundCare #HealthcareLaw

[Frier Levitt @FrierLevitt]

Healthcare providers are often familiar with medical malpractice claims and how those cases typically work. Licensing board investigations, however, follow a very different process.

Partner Alex Keoskey explains an important distinction providers should understand when dealing with a licensing board, including how the board’s role differs from the neutral court process providers may be more familiar with.

Watch the full webinar: https://t.co/p2eej5nXsa

#HealthcareLaw #MedicalLicensing #BoardInvestigations #FrierLevitt

[Frier Levitt @FrierLevitt]

Following pharmacy regulations doesn't always mean you're compliant with PBM contracts.

Learn the six common pharmacy practices that can trigger audit findings and recoupment demands, even when they're lawful: https://t.co/UfyLgNeJQM

#PBMAudits #PharmacyCompliance #FrierLevitt

[Frier Levitt @FrierLevitt]

🚨 Hiring: Regulatory Associate Attorney (Healthcare/Life Sciences)! 🚨

📍 Pine Brook, NJ or New York City (hybrid)

Looking to take the next step in your healthcare or life sciences legal career?

Frier Levitt is seeking an experienced Regulatory Associate Attorney to join our growing national healthcare, life sciences, and pharmacy law firm. This is an opportunity to work on sophisticated regulatory and compliance matters alongside attorneys with deep industry experience.

What you bring:
✔️ Experience advising clients on healthcare, life sciences, or pharmaceutical regulatory matters
✔️ Knowledge of healthcare laws and regulations, including Stark Law, Anti-Kickback Statute, False Claims Act, and HIPAA
✔️ A collaborative mindset and commitment to delivering exceptional client service
✔️ Licensed to practice in NJ (Licensed in NY, CA or other states a plus)

What we offer: highly competitive salary plus bonus potential, full benefits, unlimited PTO, 401k, and a hybrid schedule.

Ready to build your career with a firm that's growing too?

👉 Apply here: https://t.co/wssm9kbq3c

#Hiring #RegulatoryAttorney #HealthcareLaw #LifeSciences #AttorneyJobs #LegalCareers #FrierLevitt

[Frier Levitt @FrierLevitt]

New Jersey’s S-4693 targets PBM pharmacy ownership, but potential loopholes could leave vertically integrated PBMs largely unaffected.

Explore the bill’s limitations and what they mean for independent pharmacies: https://t.co/MV9By2Wjka

#PBM #PharmacyLaw #NJLegislation

[Frier Levitt @FrierLevitt]

What could the 2026 midterms mean for pharmacy policy?

Frier Levitt’s A.J. Barbarito discusses potential implications for PBM reform, reimbursement, 340B, Medicare coverage for pharmacist services and more in a Q&A with Drug Topics. 🔗 https://t.co/M3U18M5Wo8

#Pharmacy #PBM #340B #FrierLevitt

[Frier Levitt @FrierLevitt]

New federal legislation could reshape physician practice ownership and MSO arrangements.

The proposed Stop Corporate Takeovers of Physicians Act would establish a federal CPOM framework and impose new restrictions and enforcement mechanisms.

🔗 Read more: https://t.co/r6CvdokIgA

#CPOM #HealthcareLaw #FrierLevitt

[Frier Levitt @FrierLevitt]

Client Victory: Frier Levitt secured a full waiver of a Medicaid dental audit overpayment demand for a pediatric dental practice, leaving the practice with $0 in remaining liability.

🔗 Learn more about the defense strategy and key takeaways for dental providers. https://t.co/ElasgXG2CI

#Medicaid #DentalAudit #HealthcareLaw #FrierLevitt

[Frier Levitt @FrierLevitt]

As AI becomes more integrated into healthcare, medical practices face evolving questions around privacy, consent, vendor oversight, and professional liability.

🔗 Here are 5 key legal takeaways for providers using or evaluating AI technologies: https://t.co/tvRRJLDLuF

#HealthcareAI #HealthcareLaw #AI #FrierLevitt

[Frier Levitt @FrierLevitt]

340B contract pharmacy revenue is facing growing pressure from eligibility changes, manufacturer restrictions, HRSA’s rebate model, and evolving contract terms.

🔗 What should covered entities be doing now? Read more: https://t.co/WhoFPNsSPZ

#340B #ContractPharmacy #HealthcareLaw

[Frier Levitt @FrierLevitt]

Frier Levitt is exhibiting at the NCPA 2026 Annual Convention & Expo in Kansas City this weekend. Visit us at Booth #221.

Independent pharmacies face significant legal, regulatory, and reimbursement challenges. Our team will be on site to speak with pharmacy owners and professionals about the issues affecting their businesses.

Have a specific issue you want to discuss? Schedule time with our team in advance or stop by Booth #221 during the convention.

🔗 https://t.co/Ip2mgC4dbg

#NCPA2026 #IndependentPharmacy #PharmacyLaw #PBM #FrierLevitt

[Frier Levitt @FrierLevitt]

CVS is terminating existing 340B agreements and rolling out new terms for 2027 as five federal lawsuits brought by 340B hospitals remain pending.

Covered entities should carefully review the new terms before the Dec. 1 deadline.

Read more in 340B Report (subscription required): https://t.co/ZdCryQYnVF

#340B #ContractPharmacy #FrierLevitt

[Frier Levitt @FrierLevitt]

What do Board of Pharmacy inspectors look for, and which deficiencies commonly result in findings?

Article 3 of our pharmacy inspection series covers controlled substances, storage, documentation, staffing, compounding and more. 🔗 Read more: https://t.co/yu75D0Pyxx

#PharmacyLaw #PharmacyCompliance #FrierLevitt

[Frier Levitt @FrierLevitt]

CVS is issuing new 340B contracts and termination notices, with a December 1 deadline to sign.

Covered entities should carefully evaluate the impact on reimbursement, audit rights, dispute resolution and potential claims before signing.

🔗 Read more: https://t.co/nO2kr1RbM6

#340B #PharmacyLaw #FrierLevitt

[Frier Levitt @FrierLevitt]

The FDA is increasing scrutiny of compounded GLP-1 combination products.

A recent Warning Letter focuses on production volume, templated “significant difference” documentation and technology platforms as potential evidence of “pretextual” compounding.

Read more: https://t.co/T2HlI4RlVP

#FDA #GLP1 #Compounding